A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Exclusion Criteria

• •History of a human immunodeficiency virus infection or acute or chronic active hepatitis B or C infection.
• •History or presence of clinically relevant central nervous system (CNS) pathology.
• •Unresolved Grade 1-2 Immune effector cell-associated neurotoxicity syndrome (ICANS) or experienced Grade 3-4 ICANS from prior chimeric antigen receptor T-cell.
• •Unresolved graft-versus-host disease (GvHD) or Grade 3-4 acute GvHD from any prior therapy or moderate to severe chronic GvHD from any prior therapy.
• •History of any one of the following cardiovascular conditions: class III or IV heart failure as defined by the New York Heart Association \[The Criteria Committee of the New York Heart Association 1994\], cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically meaningful cardiac disease, within the past 6 months of study informed consent.
• •History of malignancies, other than R/R NHL, unless the participant has been disease-free for ≥ 1 year (certain noninvasive malignancies are allowed).
• •Active primary, CNS-only, or systemic plus CNS involvement by lymphoma, unless the CNS involvement has been effectively treated.
• •Active autoimmune disorders or inflammatory conditions that require systemic immunosuppressive therapies, including therapeutic doses of steroids.
• •Has received prior allogeneic HCT or prior solid organ transplant.
• •Systemic bacterial, viral, fungal, or other infection that is untreated or unresponsive to appropriate treatment (or requires IV antibiotics at enrollment); participants must be afebrile for ≥ 48 hours. Prophylactic antibiotics, antivirals, and antifungals are permitted.
• •Concurrent serious uncontrolled or unresolved medical condition, including any laboratory abnormality or psychiatric illness.
• •The following therapies within defined periods prior to the conditioning regimen: therapeutic doses of corticosteroids (\> 0.5 mg/kg/day of prednisone or equivalent), lymphodepleting chemotherapeutic agents, live attenuated vaccines, prior systemic cancer therapy, investigational agents, including approved drugs being used off label, autologous HCT, donor lymphocyte infusions, radiation, alemtuzumab.
• •Female who is breastfeeding or pregnant.
• •Inability or unwillingness to comply with study procedures.
• •Unwilling to use protocol specified contraceptive methods.
• •Life expectancy of ≤ 8 weeks.
• •For participants being considered for retreatment: had a DLT with prior ATA3219 dose.